warm autoimmune hemolytic anemia waiha newsletter

Autoimmune hemolytic anemia (AIHA) is a rare acquired autoimmune disease. It is caused by the dysfunction in the immune system in which the immune system attacks its red blood cells considering them foreign substances. Warm Autoimmune Hemolytic Anemia (WAIHA) is a rare but serious autoimmune disorder in which the body’s immune system mistakenly produces antibodies that attack and destroy its own red blood cells (RBCs), leading to hemolysis. This destruction primarily occurs at normal body temperature, hence the term “warm.”

If the hemolysis takes place at 37 °C, it is referred to as Warm autoimmune hemolytic anemia. WAIHA accounts for 60-70% of the total AIHA cases.

DelveInsight's brings another addition to its Newsletter Series, focusing on rare, life-threatening disease of the blood. Warm Autoimmune Hemolytic Anemia is a complex condition requiring multidisciplinary care. Prompt recognition, appropriate diagnostic work-up, and tailored therapeutic strategies are essential for effective management. With advances in immunotherapy and a better understanding of autoimmune mechanisms, the future looks promising for patients with WAIHA.

The newsletter provides a brief introduction of the indication - Warm autoimmune hemolytic anemia, its epidemiological analysis, prevalence, marketed therapies, unmet needs, and pipeline therapies in the market.

The newsletter presents the analysis of the present Warm autoimmune hemolytic anemia market scenario, key pharma companies working to drive the WAIHA market in the coming decade, key collaborations, and partnerships that are driving the market.

Download the newsletter to know more.

Subscribe and Stay in the loop.